HQY surpasses second-quarter expectations on robust HSA growth and improved margins. It also raises FY25 guidance.
Vous n'êtes pas connecté
The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.
HQY surpasses second-quarter expectations on robust HSA growth and improved margins. It also raises FY25 guidance.
HQY surpasses second-quarter expectations on robust HSA growth and improved margins. It also raises FY25 guidance.
DOCU's second-quarter fiscal 2025 earnings and revenues increase year over year.
DOCU's second-quarter fiscal 2025 earnings and revenues are likely to increase year over year.
BRZE's second-quarter fiscal 2025 earnings and revenues are likely to increase year over year.
FEIM reports a strong Q1 for fiscal 2025, with EPS and revenues rising 14% and 22%, respectively. Growth in satellite payloads and improved margins...
EVI reports a 7.7% EPS increase in Q4 2024 despite a 4% drop in revenues, supported by higher-margin parts and services, along with improved gross...
NIO reports better-than-expected second-quarter results and expects third-quarter 2024 vehicle deliveries in the range of 61,000-63,000 units.
ALK raises its third-quarter 2024 adjusted earnings per share guidance to the range of $2.15-$2.25 from the previously guided range of $1.40 to $1.60.
ALK raises its third-quarter 2024 adjusted earnings per share guidance to the range of $2.15-$2.25 from the previously guided range of $1.40 to $1.60.